AHR and breast carcinoma: Overall, our data demonstrated that FICZ, as an AhR agonist could induce the expression of tumorsuppressor miRNAs, miR-22, miR-515-5p, and miR-124-3p; thus, FICZ might be regarded as a potential therapeuticagent for breast cancer treatment.